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Abstract 
 
 
  The proto-oncogene bcl-2 is associated with follicular lymphoma involving translocation t (14; 18) 
(q32;  q21)  and  is  also  over  expressed  in  various  neoplasms.  Investigations  into  the  sequential  over 
expression of this oncoprotein in precancerous and cancerous lesions of the oral mucosa are lacking, and 
the possible role of bcl-2 in oral tumour progression remains unknown.  
Objectives:  Objectives  of  the  study  were  to  evaluate  the  expression  of  bcl-2  oncoprotein  in  severe 
epithelial dysplasia and different grades of Oral squamous cell carcinoma. 
Methods : Immunohistochemical analysis were carried out in 10 cases of severe epithelial dysplasia & 10 
cases each of well differentiated, moderately differentiated and poorly differentiated oral squamous cell 
carcinomas. 
Results & Conclusion: - Over expression of this oncoprotein was seen in severe epithelial dysplasia 
involving  entire  thickness  of  the  epithelium  with  its  down  regulation  in      differentiating  carcinomas, 
suggesting the role of this oncoprotein in early stages of tumour progression.         
 
Introduction 
  Oral  cancer  is  one  of  the  most 
formidable  health  problems  in  terms  of 
morbidity  and  mortality  facing  the  mankind 
today.    It  is  the  sixth  most  common  cancer 
worldwide accounting for 4% of all malignancies 
in  men  and  2%  in  women1.    Despite  the 
advances  in  the  detection  and  management  of 
cancers, survival rates have remained poor with a 
5 year mortality rate of 50%1,2. 
      Recent  studies  on 
cancer  have  shown  that  the  process  of 
carcinogenesis  may  involve  not  only  increased 
cell proliferation but also decreased apoptosis or 
increased cell survival3.  Normally the elimination 
of  genetically  damaged  cells  by  apoptosis 
precludes the development of tumors.  On the 
contrary, an imbalance of the apoptotic pathway 
contributes to the immortalization of replicating 
cells,  thus  favoring  the  accumulation  of 
sequential  genetic  damage  that  normally  would 
induce cell death4,5. 
  Deregulation  of  oncogenes  and  tumor 
suppressor  genes  have  been  associated  with 
tumor  development  and  progression5.    Some 
proto-oncogenes  are  known  to  prevent 
apoptosis.  The  bcl-2  is  an  important  member 
having a relevant role in tumor development by 
inhibiting apoptosis. 
  The term bcl-2 is an acronym for B cell 
lymphoma/leukemia – 2 gene6.  The human bcl-
2  protein  is an  intracellular, integral  membrane 
protein,  with  a  molecular  mass  of  ~26Kda6.  
They  are  found in  the  nuclear  envelope,  outer 
mitochondrial membrane, plasma membrane and 
endoplasmic  reticulum6,7.    This  was  first 
discovered  in  B  cell  lymphomas  with  a 
chromosomal  translocation  t  (14:18)  (q32:q21) 
and  is  associated  with  the  development  of 
lymphomas7.    This  cytogenetic  abnormality 
places the bcl-2 gene from chromosome 18 into 
juxtaposition  with  the  transcriptionally  active 
immunoglobulin  heavy-chain  locus  on 
chromosome 14, resulting in inappropriately high 
levels  of  bcl-2  gene  expression6.  The  protein 
encoded  by  this  gene  contributes  to  malignant 
cell  expansion  primarily  by  prolonging  cell 
survival  rather  than  by  increasing  the  rate  of 
cellular proliferation7.   The  specific mechanism 
by  which  bcl-2  protein  extends  cell  survival 
remains  enigmatic,  but  high  levels  of  bcl-2 
protein  have  been  shown  to  delay  or  block 
programmed cell death (apoptosis) in a variety of 
circumstances. Currently, three models are used 
to explain bcl-2 function. These models describe 
bcl-2 proteins as transmembrane ion channels or 84 
 
Oral & Maxillofacial Pathology  Journal [ OMPJ ]         Vol  2      No 1   Jan- Jun 2011    ISSN 0976-1225 
 
as proteins that modulate activation of caspases 
or  as  inhibitors  of  cytochrome  c  export  from 
mitochondria8. 
  Bcl-2 is expressed in cells in proliferating 
zones and cells with long life spans and is down 
regulated  in  terminally  differentiated  cells9.  
Topographically, bcl-2 gene expression has been 
identified in basal cells of normal oral mucosa, 
but not in superficial cells8,9.  Alterations in bcl-2 
expression play a role in cellular differentiation 
and development of tumors.  Studies have shown 
that this oncoprotein has a role in early stages of 
tumor  progression  as  it  is  up  regulated  in 
sequentially  progressing  epithelial  dysplasia  and 
down regulated in differentiating carcinomas8, 10. 
  In the present study an attempt has been 
made  to  evaluate  the  expression  of  bcl-2 
oncoprotein in  oral dysplasia and carcinoma in 
order to determine whether this oncoprotein has 
a key role in early stages of tumor progression 
and  whether  this  can  be  used  as  a  marker for 
early detection and elucidation of oral cancer. 
Materials and methods. 
  The  material  for the  study  includes  40 
formalin  fixed  paraffin  embedded  tissue  blocks 
of oral squamous cell carcinoma.  Among the 40 
blocks,  10  blocks  each  from  histologically 
diagnosed  well,  moderately  and  poorly 
differentiated oral squamous cell carcinomas and 
severe  epithelial  dysplasia  were  considered  for 
immunohistochemical staining for bcl-2. 
  The  bcl-2  immunohistochemical  kit 
[Super  Sensitive  Polymer-HRP  Detection 
System-A  Biotin  Free  Detection  System 
(QD400-60K  Super  Sensitive  Polymer-HRP 
Detection  kit  HRP/DAB)]  was  obtained  from 
Biogenex Laboratories.  
Scoring 
  The bcl-2 stained sections were studied 
in detail and the tissue sections were graded as 
follows.  On light microscopic examination, only 
those  cells  exhibiting  cytoplasmic  staining  for 
bcl-2 were counted as positive.   
    Three  high  power  microscopic 
fields  were  randomly  selected  in  the  positively 
stained area in each slide.  A total of 100 cells 
were counted in each field and the percentage of 
cells immunoreactive for bcl-2 oncoprotein was 
calculated.  Each slide was scored according to 
the  grading  system  by  Singh9  et  al  which 
categorizes  more than 50%  of  cells  positive as 
+++ (3+); 25 – 50% positive as ++(2+); 10 – 
24% positive cells as +(1+); 5 – 9% positive as 
+/- and fewer than 5% positive as negative (-). 
The  statistical  analysis was performed  by  using 
Fischer‘s exact test and a probability of p <0.05 
was considered as significant. 
Results and Observations 
  Out  of  10  cases  of  severe  epithelial 
dysplasia,  8  cases  (80%)  exhibited  intense 
reactivity that involved nearly the entire thickness 
of  epithelium  and  2  cases  (20%)  exhibited 
moderate reactivity.(Fig-1) 
  All  grades  of  SCC  showed 
heterogeneous  immunoreactivity  based  on  the 
degree  of  terminal  cell  differentiation 
(keratinization).    Generally,  peripheral  cells  of 
differentiating  epithelial  islands  were  intensely 
stained  with  decreasing  immunoreactivity 
towards the centre. 
  Among  the  10  cases  of  well 
differentiated  SCC,  3  cases  (30%)  exhibited 
moderate positivity and 7 cases (70%) exhibited 
weak positivity.(Fig-2) 
  Of  the  10  cases  of  moderately 
differentiated  SCC,  8  cases  (80%)  exhibited 
moderate positivity and 2 cases (20%) exhibited 
intense immunoreactivity.(Fig-3) 
  However  in  10  cases  of  poorly 
differentiated  SCC,  4  cases  (40%)  exhibited 
moderate  positivity  and  the  remaining  6  cases 
(60%) exhibited intense reactivity.(fig-4) 
  Correlation  between  histopathologic 
diagnoses  and  degrees  of  bcl-2  expression  in 
severe epithelial dysplasia and different grades of 
oral SCC were tabulated.  (Table I). 
  Comparison  was  made  between  each 
group  of  well,  moderately  and  poorly 
differentiated  SCC’s  for  the  degree  of  bcl-2 
expression using Fischer’s exact test. 
  While  comparing  the  degree  of  bcl-2 
expression in well and moderately differentiated 
SCC, it was found to be statistically significant 
(p<0.05) (Table II). 
  While  comparing  the  degree  of  bcl-2 
expression in well and poorly differentiated SCC, 
it was  also  found  to  be  statistically  significant. 
(p<0.05) (Table III).  
 Finally, on comparing the degree of bcl-
2  expression  in  moderately  and  poorly 
differentiated  SCC,  it  was  also  found  to  be 
statistically significant (Table IV). 
 
 
TABLE I: CORRELATION BETWEEN HISTOPATHOLOGIC DIAGNOSIS AND DEGREE 
OF bcl-2 EXPRESSION IN ORAL DYSPLASIA AND CARCINOMA 
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  Degree of bcl-2 Expression 
Diagnosis (No.of cases)  +++  ++  +  +  - 
Severe dysplasia (10)  8  2  0  0  0 
Poorly differentiated (10)  6  4  0  0  0 
Mod. differentiated (10)  0  8  2  0  0 
Well differentiated (10)  0  3  7  0  0 
 
TABLE II: COMPARISON BETWEEN DEGREE OF bcl-2 EXPRESSION IN WELL AND 
MODERATELY DIFFERENTIATED ORAL SCC 
 
Diagnosis 
Degree of bcl-2 Expression 
++  + 
Well differentiated SCC  3  7 
Mod. differentiated SCC  8  2 
 
TABLE III: COMPARISON BETWEEN DEGREE OF bcl-2 EXPRESSION IN WELL AND 
POORLY DIFFERENTIATED  
ORAL SCC 
 
Diagnosis 
Degree of bcl-2 Expression 
+++  ++/+ 
Well differentiated SCC  0  10 
Poorly differentiated SCC  6  4 
 
 
TABLE IV: COMPARISON BETWEEN DEGREE OF bcl-2 EXPRESSION IN 
MODERATELY AND POORLY DIFFERENTIATED ORAL SCC 
 
Diagnosis 
Degree of bcl-2 Expression 
+++  ++/+ 
Moderately differentiated SCC  0  10 
Poorly differentiated SCC  6  4 
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Fig -1 Severe epithelial dysplasia – bcl-2   
 
 
  Fig -2 Well Differentiated SCC bcl-2   
 
 
 
  Fig -3 Moderately  Differentiated SCC bcl-2   
 
Fig -4 Poorly  Differentiated SCC  bcl-2   
 
Discussion 
  This study demonstrates deregulation of 
bcl-2  oncoprotein  expression  in  10  cases  each 
from  severe  epithelial  dysplasia  and  varying 
grades of oral SCC.  It was found that bcl-2 was 
over  expressed  in  cells  with  histopathologic 
features of epithelial dysplasia and in peripheral 
cells of the  islands  of differentiating  squamous 
cell  carcinomas.  Moderately  and  poorly 
differentiated  SCC  also  over  expressed  this 
oncoprotein with a diffuse and intense staining 
pattern.  But,  there  was  a  decrease  in  bcl-2 
immunoreactivity in terminally differentiated cells 
(keratinizing cells). 
  In  the  10  cases  of  severe  epithelial 
dysplasia,  8  cases  (80%)  showed  intense 
immunoreactivity  and  2  cases  (20%)  exhibited 
moderate  reactivity.    There  was  a  marked 
immunoreactivity that nearly involved the entire 
thickness  of  the  epithelium  with  diminishing 
reaction to  the superficial  layers.    This  finding 
was in accordance with the findings of Singh9 et 
al, Bronner11 et al , Lai Fa Shu12 et al & Birchall13 
et  al.  This  may  be  due  to  the  inhibition  of 
apoptosis and offer an advantage to the rapidly 
growing tumor by slowing down the cell death 
rate14. This enhancement of bcl-2 expression in 
epithelial dysplasia may be a factor in early stages 
of carcinogenesis. Our observations support the 
hypothesis  that  the  enhanced  bcl-2  expression 
which  prevents  apoptosis  may  be  a  common 
early  event  and  play  an  important  role  in  the 
development of some tumors of epithelial origin. 
Many  studies  have  shown  that 
transformation rate of oral dysplasia to invasive 
carcinoma is approximately 13.8%15.  The genetic 
events associated with the evolution of epithelial 
dysplasia  to  invasive  carcinoma  have  not  been 
well  characterized,  but  alteration  of  oncogenes 
and  tumor  suppressor  genes  have  been 
reported15. In severe epithelial dysplasia there was 87 
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intense bcl-2 immunoreactivity involving almost 
the entire thickness of the epithelium. Studies of 
bcl-2  expression  in  dysplastic  lesions  at  other 
sites  have  also  shown  an up  regulation  of  this 
protein16.    They  had  proposed  that  this  up 
regulation permits prolonged cell survival and a 
selective  growth  advantage  to  the  dysplastic 
epithelial cells and then will exist the potential for 
emergence  of  a  neoplastic  clone  of  cells 
susceptible to a further mutagenic event2.  
    Attempts  were  also  made  to 
assess  the  expression  of  bcl-2  oncoprotein  in 
various  grades  of  oral  SCC  and  found  over 
expression  was  most  common  in  poorly 
differentiated  group  where  6/10  cases  (60%) 
exhibited  intense  immunoreactivity  and  the 
remaining 4 cases (40%) showed only moderate 
staining  intensity.    By  contrast,  in  well-
differentiated group, 7/10 cases (70%) exhibited 
weak  immunoreactivity  and  3/10  cases  (30%) 
showed  moderate  intensity.    Moreover,  in 
differentiated  tumors,  it  was  found  that  the 
peripheral  cells  of  the  tumor  islands  showed 
marked over expression with decreasing intensity 
towards the  centre (Keratinizing  areas).   These 
findings  were  also  consistent  with  the  earlier 
studies2,17   
The  over  expression  pattern  in 
moderately  differentiated  squamous  cell 
carcinomas  falls  in  between  well  and  poorly 
differentiated groups in which 8/10 cases (80%) 
showed  moderate  staining  intensity  and  2/10 
cases  (20%)  showed  intense  immunoreactivity. 
These findings are consistent with certain tumors 
at other sites such as colorectal neoplasia18, small 
cell lung carcinoma19, etc where bcl-2 expression 
is  linked  to  poorer  tumor  differentiation.  This 
further emphasizes the over expression of bcl-2 
in  poorly  differentiated  carcinomas  and  down 
regulation in well differentiated carcinomas.  
In  the  present  study,  the  bcl-2 
expression  in  poorly  differentiated  OSCC  was 
intense  and  this  finding  is  in  accordance  with 
earlier  findings.  We  hypothesize  that  this  up 
regulation may reflect the lost ability of malignant 
keratinocytes  for  terminal  differentiation  and 
suggest  that  those  cells  over  expressing  bcl-2 
have a stem cell phenotype.  A predominance of 
bcl-2 has an ant apoptotic effect on the cells and 
favours a stem cell phenotype. 
In moderately differentiated  group,  the 
bcl-2 expression was of moderate intensity falling 
between  well  and  poorly  differentiated  groups 
which  are  in  agreement  with  the  findings  by 
Martin C Jackel20et al, Leahy14 et al, &  Ravi17 et 
al. 
In  this  study,  a  direct  correlation  was 
found  between  bcl-2  immunoreactivity  and 
tumor differentiation.   That is, it is up regulated 
in  poorly  differentiated  carcinoma  and 
sequentially  down  regulated  in  moderately  and 
well  differentiated  squamous  cell  carcinomas.  
This down regulation of bcl-2 in differentiating 
carcinomas  indicates that this  oncoprotein  may 
play a key role in progression of oral neoplasia.  
    This  study  demonstrates  bcl-2 
oncoprotein over expression in all phases of oral 
neoplasia, and we conclude that it may play a key 
role in the early stages of oral tumor genesis. In 
addition, bcl-2 expression appears to be inversely 
related to the degree of epithelial differentiation.  
Conclusion 
  This study suggests that the bcl-2 protein 
participates  in  the  control  of  terminal 
differentiation  of  normal  oral  keratinocytes  by 
protecting their stem cells from apoptosis.  Also, 
the  results  of  the  current  study  highlight  the 
possibility that bcl-2 may be effectively employed 
to characterize oral SCC better and to possibly 
predict its biologic behavior. 
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